Molecular Entomology 2024, Vol.15, No.1, 18-22 http://emtoscipublisher.com/index.php/me 20 2 Insights of Research Findings Trametinib, a MEK inhibitor, significantly extends lifespan and improves intestinal health in female Drosophila through intensive research. The study showed that Trametinib significantly extended lifespan in all female Drosophila trials and improved the pathology of the intestinal epithelium by reducing the proliferation of intestinal stem cells (ISCs), and that Trametinib has a significant impact on the maintenance of the intestinal barrier. In the study, a non-absorbent blue dye test showed that Trametinib significantly reduced intestinal barrier leakage in aged female Drosophila, a so-called "smurf" phenomenon that is commonly associated with a loss of intestinal barrier function. This result suggests the potential value of Trametinib in maintaining the integrity of the intestinal barrier, which may have a positive effect on slowing the degradation of intestinal function associated with aging. The study also explored the mechanism of action of Trametinib, particularly its function in regulating the activity of Pol III, a key transcription factor responsible for the synthesis of small-molecule RNAs, such as tRNA, which is closely related to protein synthesis in cells. The study found that Trametinib prolongs life span and reduces intestinal pathology in Drosophila by inhibiting Pol III activity in intestinal stem cells. This study not only enhances the understanding of Trametinib as an anti-cancer drug, but also demonstrates its potential in the anti-aging field. By delving into its biological effects in a Drosophila model, the study provides a scientific basis for future clinical applications of such drugs to slow the aging process in humans. These findings are expected to advance broader biomedical research and explore new anti-aging strategies. Figure 4 Trametinib reduces Pol III activity and interacts with Pol III inhibition
RkJQdWJsaXNoZXIy MjQ4ODY0NQ==